SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hirsh, J. Articles by Lee, A. Y. Y. Search for Related Content PubMed PubMed Citation Articles by Hirsh, J. Articles by Lee, A. Y. Y. Related Collections Hemostasis, Thrombosis, and Vascular Biology How I Treat Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 May 2002, Vol. 99, No. 9, pp. 3102-3110 HOW I TREAT How we diagnose and treat deep vein thrombosis Jack Hirsh and Agnes Y. Y. Lee From the Henderson Research Centre, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada Making a diagnosis of deep vein thrombosis (DVT) requires both clinical assessment and objective testing because the clinical features are nonspecific and investigations can be either falsely positive or negative. The initial step in the diagnostic process is to stratify patients into high-, intermediate-, or low-risk categories using a validated clinical model. When the clinical probability is intermediate or high and the venous ultrasound result is positive, acute symptomatic DVT is confirmed. Similarly, when the probability is low and the ultrasound result is normal, DVT is ruled out. A low clinical probability combined with a negative D-dimer result can also be used to rule out DVT, thereby obviating the need for ultrasonography. In contrast, when the clinical assessment is discordant with the results of objective testing, serial venous ultrasonography or venography is required to confirm or refute a diagnosis of DVT. Once a patient is diagnosed with an acute DVT, low-molecular-weight heparin (LMWH) is the agent of choice for initial therapy and oral anticoagulant therapy is the standard for long-term secondary prophylaxis. Therapy should continue for at least 3 months; the decision to continue treatment beyond 3 months is made by weighing the risks of recurrent thrombosis and anticoagulant-related bleeding, and is influenced by patient preference. Screening for associated thrombophilia is not indicated routinely, but should be performed in selected patients whose clinical features suggest an underlying hypercoagulable state. Several new anticoagulants with theoretical advantages over existing agents are undergoing evaluation in phase 3 studies in patients with venous thromboembolism. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Modarai, J. Humphries, J.A. Gossage, M. Waltham, K.G. Burnand, G.S. Kanaganayagam, A. Afuwape, E. Paleolog, A. Smith, and A. Wadoodi Adenovirus-Mediated VEGF Gene Therapy Enhances Venous Thrombus Recanalization and Resolution Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1753 - 1759. [Abstract] [Full Text] [PDF] S.I.R. Noble, K. Hood, and I.G. Finlay The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients Palliative Medicine, September 1, 2007; 21(6): 473 - 476. [Abstract] [PDF] T. Brighton, J. Janssen, and S. P. Butler Aging of Acute Deep Vein Thrombosis Measured by Radiolabeled 99mTc-rt-PA J. Nucl. Med., June 1, 2007; 48(6): 873 - 878. [Abstract] [Full Text] [PDF] N. M. Milovic, J. R. Behr, M. Godin, C.-S. J. Hou, K. R. Payer, A. Chandrasekaran, P. R. Russo, R. Sasisekharan, and S. R. Manalis Monitoring of heparin and its low-molecular-weight analogs by silicon field effect PNAS, September 5, 2006; 103(36): 13374 - 13379. [Abstract] [Full Text] [PDF] A. Falanga and L. Zacharski Deep vein thrombosis in cancer: the scale of the problem and approaches to management Ann. Onc., May 1, 2005; 16(5): 696 - 701. [Abstract] [Full Text] [PDF] R. Oudega, K. G. Moons, and A. W Hoes Limited value of patient history and physical examination in diagnosing deep vein thrombosis in primary care Fam. Pract., February 1, 2005; 22(1): 86 - 91. [Abstract] [Full Text] [PDF] S. Siragusa, R. Anastasio, C. Porta, F. Falaschi, S. Pirrelli, P. Palmieri, G. Gamba, K. Granzow, A. Malato, V. Minardi, et al. Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis: A Practical Approach Based on the Pretest Clinical Model, D-Dimer Testing, and the Use of Low-Molecular-Weight Heparins Arch Intern Med, December 13, 2004; 164(22): 2477 - 2482. [Abstract] [Full Text] [PDF] P. Prandoni, E. Bernardi, A. Marchiori, A. W A Lensing, M. H Prins, S. Villalta, P. Bagatella, D. Sartor, A. Piccioli, P. Simioni, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study BMJ, August 28, 2004; 329(7464): 484 - 485. [Full Text] [PDF] M. Alifano, G. Benedetti, and R. Trisolini Can Low-Molecular-Weight Heparin Improve the Outcome of Patients With Operable Non-Small Cell Lung Cancer?: An Urgent Call for Research Chest, August 1, 2004; 126(2): 601 - 607. [Full Text] [PDF] M Riedel Diagnosing pulmonary embolism Postgrad. Med. J., June 1, 2004; 80(944): 309 - 319. [Abstract] [Full Text] [PDF] S. M. Rezende, R. E. Simmonds, and D. A. Lane Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex Blood, February 15, 2004; 103(4): 1192 - 1201. [Abstract] [Full Text] [PDF] S. Eichinger, E. Minar, C. Bialonczyk, M. Hirschl, P. Quehenberger, B. Schneider, A. Weltermann, O. Wagner, and P. A. Kyrle D-Dimer Levels and Risk of Recurrent Venous Thromboembolism JAMA, August 27, 2003; 290(8): 1071 - 1074. [Abstract] [Full Text] [PDF] C. J.J. van Dongen, M. H. Prins, H. R. Buller, C. Seneviratne, Y. Kupfer, S. Tessler, J. A. Krishnan, M. B. Streiff, B. Cosmi, G. Palareti, et al. Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism N. Engl. J. Med., July 24, 2003; 349(4): 398 - 400. [Full Text] [PDF] J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF] M. J. Kovacs, M. Rodger, D. R. Anderson, B. Morrow, G. Kells, J. Kovacs, E. Boyle, and P. S. Wells Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism: A Randomized, Double-Blind, Controlled Trial Ann Intern Med, May 6, 2003; 138(9): 714 - 719. [Abstract] [Full Text] [PDF] D. G. Hackam Long-term, low-intensity warfarin after idiopathic venous thromboembolism Can. Med. Assoc. J., April 29, 2003; 168(9): 1160 - 1161. [Full Text] [PDF] J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF] M. Sundaram, Y. Qi, Z. Shriver, D. Liu, G. Zhao, G. Venkataraman, R. Langer, and R. Sasisekharan Rational design of low-molecular weight heparins with improved invivo activity PNAS, January 21, 2003; 100(2): 651 - 656. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020